↓ Skip to main content

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

Overview of attention for article published in Clinical Cancer Research, April 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
1 X user
patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
133 Dimensions

Readers on

mendeley
155 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Published in
Clinical Cancer Research, April 2014
DOI 10.1158/1078-0432.ccr-13-2054
Pubmed ID
Authors

Alexander M. Menzies, Georgina V. Long

Abstract

Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and most recently, their use in combination has received accelerated FDA approval. Both drugs target the mitogen-activated protein kinase (MAPK) pathway: dabrafenib selectively inhibits mutant BRAF that constitutively activates the pathway, and trametinib selectively inhibits MEK1 and MEK2 proteins activated by RAF kinases. The phase III study of dabrafenib in BRAF(V600E) metastatic melanoma reported rapid tumor regression in most patients and a 59% objective RECIST response rate. The median progression-free survival (PFS) and overall survival (OS) were improved compared with dacarbazine. Toxicities were well tolerated and different from those reported for vemurafenib, the first FDA-approved BRAF inhibitor. Efficacy has been demonstrated in other BRAF-mutant genotypes. The phase III study of trametinib in BRAF inhibitor-naïve patients with BRAF(V600E) or BRAF(V600K) also showed benefit with a prolonged median PFS and OS compared with chemotherapy. Trametinib is ineffective in patients who have progressed on BRAF inhibitors. A phase II trial of combined dabrafenib and trametinib demonstrated higher response rates and longer median PFS than dabrafenib monotherapy, with less cutaneous toxicity. Here, we review the clinical development of both drugs as monotherapies and in combination, and discuss their role in the management of BRAF-mutant melanoma.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
United Kingdom 1 <1%
Romania 1 <1%
United States 1 <1%
Poland 1 <1%
Unknown 150 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 36 23%
Student > Ph. D. Student 25 16%
Student > Bachelor 20 13%
Student > Master 18 12%
Student > Doctoral Student 12 8%
Other 19 12%
Unknown 25 16%
Readers by discipline Count As %
Medicine and Dentistry 38 25%
Biochemistry, Genetics and Molecular Biology 35 23%
Agricultural and Biological Sciences 21 14%
Pharmacology, Toxicology and Pharmaceutical Science 12 8%
Chemistry 8 5%
Other 13 8%
Unknown 28 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2024.
All research outputs
#5,312,632
of 25,352,304 outputs
Outputs from Clinical Cancer Research
#4,695
of 13,217 outputs
Outputs of similar age
#48,398
of 233,661 outputs
Outputs of similar age from Clinical Cancer Research
#66
of 201 outputs
Altmetric has tracked 25,352,304 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,217 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,661 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 201 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.